Abstract
Compounding for the Treatment of COVID-19 and Long COVID, Part 1: Terminology, Mutations, and Variants
Author(s): Riepl Mike
Issue: Jan/Feb 2023 - Volume 27, Number 1
Page(s): 12-21
Abstract
COVID-19 (coronavirus disease 2019), which is caused by the positive-stranded ribonucleic acid virus SARS-CoV-2 (acute respiratory syndrome coronavirus 2), is an extremely contagious airborne illness of pandemic proportions. In the modern era, few diseases other than COVID-19 have produced such severe, prolific, and protean short-term adverse effects and long-term sequelae. In addition, few other pandemics have exhibited a trajectory of morbidity and mortality so affected by social, economic, and political factors as well as individual personal perceptions and beliefs. Vaccines for the prevention of SARS-CoV-2 infection and treatments for COVID-19 mitigate associated morbidity and mortality, but an increasing array of variants presents challenges to therapeutic effectiveness. As a result, afflicted patients often require customized treatments that address the severity of their infection, the manifestations of disease they exhibit, and their individual pharmacogenomic profile. In such cases, a compounded preparation may offer needed support for recovery. This article, which is the first in a series on compounding for COVID-19 and long COVID (i.e., the long- term sequelae of SARS-CoV-2 infection), provides information about pertinent viral terminology and a brief overview of SARS-CoV-2 mutations and variants of note. Two formulations for customized compounds that may prove effective in treating the acute and/or long-term effects of COVID-19 when commercial therapies have failed are also provided.
Related Keywords
- COVID-19
- long COVID
- coronavirus disease 2019
- SARS-CoV-2 virus
- acute respiratory syndrome coronavirus 2
- pandemic
- genetic variants
- mutations
- mutants
- terminology
- inflammation
- proinflammatory cytokines
- inflammatory response
- lungs
- airway
- immune cell recruitment
- complement cascade activation
- formulations
- D614G
- naltrexone hydrochloride
- N501Y
- E484K
- alpha variant
- beta variant
- gamma variant
- delta variant
- omicron variant
Related Categories
- FORMULATIONS
- INFECTIOUS DISEASE
Related Articles from IJPC
| Issue/Page View/Buy |
Title/Author (Click for Abstract / Details / Purchase) |
|---|---|
|
Jan/Feb 2023
Pg. 12-21
|
Author(s):
Riepl Mike
|
|
Jul/Aug 2023
Pg. 284-293
|
Author(s):
Riepl Mike, Kaiser Joe
|
|
May/Jun 2023
Pg. 192-200
|
Author(s):
Riepl Mike, Kaiser Joe
|
|
Mar/Apr 2023
Pg. 98-107
|
Author(s):
Riepl Mike
|
|
Sep/Oct 2023
Pg. 368-380
|
Author(s):
Riepl Mike, Kaiser Joe
|
|
Jul/Aug 2020
Pg. 287-295
|
Author(s):
McElhiney Linda F
|
|
Jul/Aug 2020
Pg. 268
|
Author(s):
Allen Loyd V Jr
|
|
Sep/Oct 2020
Pg. 358-364
|
|
|
Mar/Apr 2021
Pg. 109-113
|
|
|
Jul/Aug 2003
Pg. 288-291
|
Author(s):
Glasnapp Andrew
|
|
Jul/Aug 2020
Pg. 316
|
Author(s):
Allen Loyd V Jr
|
|
Jul/Aug 2020
Pg. 310
|
Author(s):
Stockton Shelly J
|
|
Jul/Aug 2021
Pg. 268
|
Author(s):
Allen Loyd V Jr
|
|
Jul/Aug 2003
Pg. 266-270
|
Author(s):
Kuntz Rachael
|
|
Sep/Oct 2022
Pg. 432-435
|
Author(s):
Marianni Bruna, Polonini Hudson
|
|
Jul/Aug 2016
Pg. 347-350
|
|
|
Jul/Aug 2021
Pg. 296-297
|
Author(s):
Brunner Scott
|
|
Sep/Oct 2021
Pg. 386-387
|
Author(s):
Brunner Scott
|
|
May/Jun 2003
Pg. 188-191
|
Author(s):
Davidson Gigi S
|
|
Mar/Apr 2022
Pg. 100-109
|
Author(s):
Broughel James
|